Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 5/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14032489 | 1.00 | TAAR1 (0.59) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL13248740 | 1.00 | TAAR1 (0.59) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL15290220 | 0.85 | TAAR1 (0.52) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL23643109 | 0.84 | EPHX1 (0.50) | TAAR1SLC6A2ESR1CA2EPHX1 | |
| SCHEMBL22937469 | 0.84 | EPHX1 (0.50) | TAAR1SLC6A2ESR1EPHX1 | |
| SCHEMBL22593510 | 0.84 | EPHX1 (0.50) | TAAR1EPHX1GAA | |
| SCHEMBL23643108 | 0.84 | EPHX1 (0.50) | TAAR1SLC6A2EPHX1SMN1; SMN2 | |
| SCHEMBL12118748 | 0.84 | EPHX1 (0.50) | TAAR1EPHX1GAA | |
| SCHEMBL7753247 | 0.83 | TAAR1 (0.57) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL19606520 | 0.83 | TAAR1 (0.49) | TAAR1SLC6A2SLC7A5ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564971-B2 | Hyaluronic acid derivative having amino acid and steryl group introduced thereinto | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20220160849-A1 | CANCER VACCINE FORMULATION | MIE UNIVERSITY (JP) | 2022-05-26 | — | — | US | disclosed |
| EP-3919072-A1 | CANCER VACCINE PREPARATION | Mie University (JP) | 2021-12-08 | — | — | EP | disclosed |
| CN-108250191-B | 3, 5-disubstituted 2-amino-pyrazine compound and preparation process and application thereof | 兰州大学 | 2020-10-20 | — | — | CN | disclosed |
| CN-102702013-B | Nuclear receptor binding agents | GTX INC. (US) | 2016-02-10 | — | — | CN | disclosed |
| US-20150231268-A1 | HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-20 | — | — | US | disclosed |
| US-20150231268-A1 | HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-20 | — | — | US | disclosed |
| EP-1844070-B1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7365090-B2 | Substituted phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365090-B2 | Substituted phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160849-A1 | CANCER VACCINE FORMULATION | CD44, TP53, MUC1 | TAAR1 4619/4885SLC6A2 4106/4885SLC7A5 983/4885 |
| US-20150231268-A1 | HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO | CD44, DAO, FUT6 | TAAR1 3191/4885SLC6A2 1083/4885SLC7A5 45/4885 |
| US-11564971-B2 | Hyaluronic acid derivative having amino acid and steryl group introduced thereinto | CD44, DAO, FUT6 | TAAR1 3191/4885SLC6A2 1083/4885SLC7A5 45/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | TAAR1 4780/4885SLC6A2 3738/4885SLC7A5 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.